Menu Search
Equities

Recce Pharmaceuticals Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
R9Q:FRA

Recce Pharmaceuticals Ltd

Actions
  • Price (EUR)0.316
  • Today's Change-0.004 / -1.25%
  • Shares traded5.00k
  • 1 Year change+30.58%
  • Beta0.1375
Data delayed at least 15 minutes, as of Feb 18 2026 07:04 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year Recce Pharmaceuticals Ltd had net income fall 21.33% from a loss of 17.66m to a larger loss of 21.43m despite a 47.14% increase in revenues from 5.24m to 7.70m.
Gross margin--
Net profit margin-278.12%
Operating margin-263.47%
Return on assets-228.15%
Return on equity--
Return on investment--
More ▼

Cash flow in AUDView more

In 2025, Recce Pharmaceuticals Ltd increased its cash reserves by 136.66%, or 6.03m. Cash Flow from Financing totalled 26.92m or 349.39% of revenues. In addition the company used 20.44m for operations while cash used for investing totalled 443.90k.
Cash flow per share-0.0889
Price/Cash flow per share--
Book value per share-0.0106
Tangible book value per share-0.0106
More ▼

Balance sheet in AUDView more

Recce Pharmaceuticals Ltd has a Debt to Total Capital ratio of 149.31%.
Current ratio1.86
Quick ratio--
Total debt/total equity--
Total debt/total capital1.49
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.